top of page
Doctor's Desk

At STOP T1D, we know that early detection leads to better outcomes.

Led by the Barbara Davis Center for Diabetes at the University of Colorado, our mission is twofold:

To raise awareness among Health Care Providers (HCP) and communities about the critical importance of early detection and the severe consequences of delayed diagnosis of Type 1 Diabetes

1

To educate and empower HCPs and healthcare organizations with the knowledge, competence, and tools necessary for effective screening, timely diagnosis, and age-specific monitoring practices. 

2

Health Care Providers must  SIGN UP  to gain full access.

See course description and learning objectives below...

 

NOTE: MODULE 1 (link below) is viewable before signing up.

HCP Educational Modules

This innovative course is designed to provide health care providers with the knowledge and tools necessary to effectively promote and/or conduct screening for pre-symptomatic type 1 diabetes (T1D). Participants will gain a comprehensive understanding of the importance of early detection and monitoring of pre-symptomatic T1D, covering:

• Screening methods and confirmation

• Target populations

• Communication of results

• Patient monitoring

• Available intervention and clinical trial opportunities

• Implementation of screening and monitoring into health systems

By the end of the course, participants will be prepared to make a significant impact on the immediate and long-term health of people living with type 1 diabetes. 

The course seeks to bring innovation directly from research to clinical care. As such, this curriculum is a living document. Course participants will be eligible to receive ongoing updates as the field evolves. 

STOP T1D program will soon offer CME credits. 

We will email all registered HCPs when this becomes available.

LEARNING OBJECTIVES
Upon completing this course, health care providers should be able to:
 

1. Understand the significance of early detection and intervention for T1D.
2. Be familiar with islet autoimmunity screening methods.
3. Explain the process of result confirmation.
4. Develop effective strategies for result notification, ensuring clarity and patient understanding.
5. Be familiar with monitoring protocols to track high-risk individuals with positive screening results.

6. Recognize the psychosocial impact of screening and monitoring on the patient and family.
7. Discuss the role of clinical trials and FDA-approved interventions in delaying onset of symptomatic T1D.
8. Collaborate with interdisciplinary teams to provide comprehensive care to individuals at high-risk of
    developing T1D.
9. Identify the key components of healthcare organizations required for effective pre-symptomatic
    diabetes screening and monitoring.
10. Describe screening strategies for relevant demographic groups.

1.png
Pathophysiology and Natural History of Type 1 Diabetes
2.png
Introduction to T1D Screening
3.png
Epidemiology of T1D and Target Populations for Screening
4.png
Screening Methods
5.png
Confirmation of Positive Screening Results
6.png
Results Notification
7.png
Psychological Impact and Engagement
8.png
Monitoring and Managing Islet Autoantibody Positive Patients
9.png
FDA Approved Treatment for Pre-Symptomatic T1D
10.png
Clinical Trials
11.png
Implementing Screening and Monitoring into Healthcare Systems

MODULES

REGISTER

Health Care Providers must sign up to gain access to these educational materials, practical advice, and algorithms for T1D screening and monitoring.

Returning HCPs (already signed up)

bottom of page